Intravenous sildenafil for the treatment of persistent pulmonary hypertension of the newborn in a resource-limited setting

Address for correspondence: Dr. Mirta Noemi Mesquita Ramirez, Department of Teaching and Research, General Pediatric Hospital Children of Acosta Ñu, Avenida Bacigalupo y de La Victoria, Reducto, San Lorenzo 111 475, Paraguay. E‑mail: mirtanmr@gmail.com

Saved in:
Bibliographic Details
Main Author: Mesquita Ramírez, Mirta (author)
Other Authors: Samudio Acevedo, Margarita (author), Cardozo Sarubbi, Olivia Carolina (author), Carrera Vargas, Dina Carmen (author), Villalba Cabral, Pedro Luis (author)
Format: article
Language:English
Published: 2023
Subjects:
Online Access:https://doi.org/10.4103/jcn.jcn_33_23
http://hdl.handle.net/20.500.14066/4507
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1870612070622298112
author Mesquita Ramírez, Mirta
author2 Samudio Acevedo, Margarita
Cardozo Sarubbi, Olivia Carolina
Carrera Vargas, Dina Carmen
Villalba Cabral, Pedro Luis
author2_role author
author
author
author
author_browse Cardozo Sarubbi, Olivia Carolina
Carrera Vargas, Dina Carmen
Mesquita Ramírez, Mirta
Samudio Acevedo, Margarita
Villalba Cabral, Pedro Luis
author_facet Mesquita Ramírez, Mirta
Samudio Acevedo, Margarita
Cardozo Sarubbi, Olivia Carolina
Carrera Vargas, Dina Carmen
Villalba Cabral, Pedro Luis
author_role author
bitstream.checksum.fl_str_mv 84e9b967554665dc6910ed1864963d9d
934f4ca17e109e0a05eaeaba504d7ce4
858b22fda432bd774e469302988c1974
29e78d750f7cac41ad08ca8e802e936c
5bd9a89a42f6eb6bdb76601e607e8682
bitstream.checksumAlgorithm.fl_str_mv MD5
MD5
MD5
MD5
MD5
bitstream.url.fl_str_mv http://repositorio.conacyt.gov.py/bitstream/20.500.14066/4507/1/Intravenous%20sildenafil%20for%20the%20treatment%20of%20persistent%20pulmonary%20hypertension%20of%20the%20newborn%20in%20a%20resource-limited%20setting.pdf
http://repositorio.conacyt.gov.py/bitstream/20.500.14066/4507/2/license_rdf
http://repositorio.conacyt.gov.py/bitstream/20.500.14066/4507/3/license.txt
http://repositorio.conacyt.gov.py/bitstream/20.500.14066/4507/4/Intravenous%20sildenafil%20for%20the%20treatment%20of%20persistent%20pulmonary%20hypertension.jpg
http://repositorio.conacyt.gov.py/bitstream/20.500.14066/4507/5/Intravenous%20sildenafil%20for%20the%20treatment%20of%20persistent%20pulmonary%20hypertension%20of%20the%20newborn%20in%20a%20resource-limited%20setting.pdf.txt
dc.contributor.other.es.fl_str_mv Universidad Católica Nuestra Señora de la Asunción
dc.creator.none.fl_str_mv Mesquita Ramírez, Mirta
Samudio Acevedo, Margarita
Cardozo Sarubbi, Olivia Carolina
Carrera Vargas, Dina Carmen
Villalba Cabral, Pedro Luis
dc.date.accessioned.none.fl_str_mv 2025-01-20T15:10:01Z
dc.date.available.none.fl_str_mv 2025-01-20T15:10:01Z
dc.date.issued.none.fl_str_mv 2023-07-12
dc.identifier.citation.en.fl_str_mv Mesquita Ramírez, M. N., Samudio Acevedo, M., Cardozo Sarubbi, O. C., Carrera, D. C., & Villalba Cabral, P. L. (2023). Intravenous sildenafil for the treatment of persistent pulmonary hypertension of the newborn in a resource limited setting. Journal of Clinical Neonatology, 12(3), 99-104. https://doi.org/10.4103/jcn.jcn_33_23
dc.identifier.doi.es.fl_str_mv 10.4103/jcn.jcn_33_23
dc.identifier.essn.es.fl_str_mv 1658-6093
dc.identifier.issn.es.fl_str_mv 2249-4847
dc.identifier.other.es.fl_str_mv https://doi.org/10.4103/jcn.jcn_33_23
dc.identifier.uri.none.fl_str_mv http://hdl.handle.net/20.500.14066/4507
dc.language.iso.es.fl_str_mv eng
dc.publisher.es.fl_str_mv Wolters Kluwer - Medknow Publications
dc.relation.projectCONACYT.es.fl_str_mv PINV15-1022
dc.rights.*.fl_str_mv Atribución-NoComercial-CompartirIgual 4.0 Internacional
dc.rights.accessRights.es.fl_str_mv info:eu-repo/semantics/openAccess
dc.rights.copyright.es.fl_str_mv © 2023 Journal of Clinical Neonatology
dc.rights.uri.*.fl_str_mv http://creativecommons.org/licenses/by-nc-sa/4.0/
dc.subject.classification.es.fl_str_mv 7. Salud
7.4. Seguimiento sanitario
dc.subject.mesh.en.fl_str_mv Sildenafil citrate
Infant
Nitrous oxide
Newborn
Persistent fetal circulation syndrome
Vasodilator agents
dc.subject.mesh.es.fl_str_mv Citrato de sildenafil
Lactante
Óxido nitroso
Recién nacido
Síndrome de circulación fetal persistente
Vasodilatadores
dc.subject.ocde.es.fl_str_mv 3. Ciencias Médicas y de la Salud
3.1. Medicina Básica (anatomía, citología, fisiología, genética, farmacia, farmacología, toxicología, inmunología e inmunohematología, química clínica, microbiología clínica, patología)
dc.subject.other.es.fl_str_mv Oxygenation index
Persistent pulmonary hypertension of the newborn
Sildenafil
dc.title.es.fl_str_mv Intravenous sildenafil for the treatment of persistent pulmonary hypertension of the newborn in a resource-limited setting
dc.type.es.fl_str_mv info:eu-repo/semantics/article
info:eu-repo/semantics/publishedVersion
description Address for correspondence: Dr. Mirta Noemi Mesquita Ramirez, Department of Teaching and Research, General Pediatric Hospital Children of Acosta Ñu, Avenida Bacigalupo y de La Victoria, Reducto, San Lorenzo 111 475, Paraguay. E‑mail: mirtanmr@gmail.com
eu_rights_str_mv openAccess
format article
id CONACYT_a586dc1c6d4ec41741fa1dae3fa135cc
identifier_str_mv Mesquita Ramírez, M. N., Samudio Acevedo, M., Cardozo Sarubbi, O. C., Carrera, D. C., & Villalba Cabral, P. L. (2023). Intravenous sildenafil for the treatment of persistent pulmonary hypertension of the newborn in a resource limited setting. Journal of Clinical Neonatology, 12(3), 99-104. https://doi.org/10.4103/jcn.jcn_33_23
2249-4847
10.4103/jcn.jcn_33_23
1658-6093
language eng
network_acronym_str CONACYT
network_name_str Repositorio Institucional CONACYT
oai_identifier_str oai:repositorio.conacyt.gov.py:20.500.14066/4507
publishDate 2023
publishDateSort 2023
repository.mail.fl_str_mv repositorio.institucional@conacyt.gov.py
repository.name.fl_str_mv Repositorio Institucional CONACYT
repository_id_str
rights_invalid_str_mv Atribución-NoComercial-CompartirIgual 4.0 Internacional
http://creativecommons.org/licenses/by-nc-sa/4.0/
© 2023 Journal of Clinical Neonatology
spelling f4cf5d89-b3ec-4271-b479-c3a809ae3c8960010346005abb1249-16c3-4e0c-9471-64fefd10d00a600a5792a5e-f1b8-4d28-88db-db7abf63b3f76001182600Universidad Católica Nuestra Señora de la Asunción2025-01-20T15:10:01Z2025-01-20T15:10:01Z2023-07-12Mesquita Ramírez, M. N., Samudio Acevedo, M., Cardozo Sarubbi, O. C., Carrera, D. C., & Villalba Cabral, P. L. (2023). Intravenous sildenafil for the treatment of persistent pulmonary hypertension of the newborn in a resource limited setting. Journal of Clinical Neonatology, 12(3), 99-104. https://doi.org/10.4103/jcn.jcn_33_232249-4847https://doi.org/10.4103/jcn.jcn_33_23http://hdl.handle.net/20.500.14066/450710.4103/jcn.jcn_33_231658-6093Address for correspondence: Dr. Mirta Noemi Mesquita Ramirez, Department of Teaching and Research, General Pediatric Hospital Children of Acosta Ñu, Avenida Bacigalupo y de La Victoria, Reducto, San Lorenzo 111 475, Paraguay. E‑mail: mirtanmr@gmail.comIntroduction: Treatment of severe persistent pulmonary hypertension of the newborn (PPHN) is based on the administration of selective pulmonary vasodilators. Inhaled nitric oxide is the only vasodilator therapy approved by the Food and Drug Administration. Non-selective vasodilator such as sildenafil has been the treatment available administered orally in most developing countries to manage newborn with PPHN. The aim of the study was to describe the effects and tolerability of intravenous (IV) sildenafil, as a loading dose of 0.4 mg/kg, followed by a continuous infusion of 1.6 mg/kg for 72 h on the oxygenation index (OI) in neonates with PPHN. Materials and Methods: This was an exploratory observational prospective study. Newborns ≥35 weeks of gestational age, post-natal age ≤72 h, with PPHN and an OI ≥20 were included in the study. Sildenafil was administered intravenously as a loading dose of 0.4 mg/kg, followed by a continuous infusion of 1.6 mg/kg for 72 h. During the sildenafil infusion, monitoring of vital signs and respiratory parameters was performed. The data were analysed with the SPSS v21. Results: Twenty-five infants were included. A significant improvement (P = 0.01) of OI (at admission, median: 25 and interquartile range [IQR] = 8) was observed at the end of the loading dose (3 h) (18 IQR = 4) and at 72 h (7 IQR = 4). No serious adverse effects were observed. Before hospital discharge, seven patients died. Conclusions: IV sildenafil administered, in newborns with PPHN with an IO ≥20, improved oxygenation in most of the patients without serious side effects.Consejo Nacional de Ciencia y TecnologíaPrograma Paraguayo para el Desarrollo de la Ciencia y Tecnología. Proyectos de investigación y desarrolloengWolters Kluwer - Medknow PublicationsAtribución-NoComercial-CompartirIgual 4.0 Internacionalhttp://creativecommons.org/licenses/by-nc-sa/4.0/info:eu-repo/semantics/openAccess© 2023 Journal of Clinical Neonatology7. Salud7.4. Seguimiento sanitarioSildenafil citrateInfantNitrous oxideNewbornPersistent fetal circulation syndromeVasodilator agentsCitrato de sildenafilLactanteÓxido nitrosoRecién nacidoSíndrome de circulación fetal persistenteVasodilatadoresOxygenation indexPersistent pulmonary hypertension of the newbornSildenafil3. Ciencias Médicas y de la Salud3.1. Medicina Básica (anatomía, citología, fisiología, genética, farmacia, farmacología, toxicología, inmunología e inmunohematología, química clínica, microbiología clínica, patología)Intravenous sildenafil for the treatment of persistent pulmonary hypertension of the newborn in a resource-limited settinginfo:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersion3Journal of Clinical Neonatology99104PINV15-102212Mesquita Ramírez, MirtaSamudio Acevedo, MargaritaCardozo Sarubbi, Olivia CarolinaCarrera Vargas, Dina CarmenVillalba Cabral, Pedro LuisORIGINALIntravenous sildenafil for the treatment of persistent pulmonary hypertension of the newborn in a resource-limited setting.pdfIntravenous sildenafil for the treatment of persistent pulmonary hypertension of the newborn in a resource-limited setting.pdfArtículo científicoapplication/pdf778414http://repositorio.conacyt.gov.py/bitstream/20.500.14066/4507/1/Intravenous%20sildenafil%20for%20the%20treatment%20of%20persistent%20pulmonary%20hypertension%20of%20the%20newborn%20in%20a%20resource-limited%20setting.pdf84e9b967554665dc6910ed1864963d9dMD51CC-LICENSElicense_rdflicense_rdfapplication/rdf+xml; charset=utf-81031http://repositorio.conacyt.gov.py/bitstream/20.500.14066/4507/2/license_rdf934f4ca17e109e0a05eaeaba504d7ce4MD52LICENSElicense.txtlicense.txttext/plain; charset=utf-81698http://repositorio.conacyt.gov.py/bitstream/20.500.14066/4507/3/license.txt858b22fda432bd774e469302988c1974MD53THUMBNAILIntravenous sildenafil for the treatment of persistent pulmonary hypertension.jpgIntravenous sildenafil for the treatment of persistent pulmonary hypertension.jpgVista de primera página de artículo científicoimage/jpeg1208957http://repositorio.conacyt.gov.py/bitstream/20.500.14066/4507/4/Intravenous%20sildenafil%20for%20the%20treatment%20of%20persistent%20pulmonary%20hypertension.jpg29e78d750f7cac41ad08ca8e802e936cMD54TEXTIntravenous sildenafil for the treatment of persistent pulmonary hypertension of the newborn in a resource-limited setting.pdf.txtIntravenous sildenafil for the treatment of persistent pulmonary hypertension of the newborn in a resource-limited setting.pdf.txtExtracted texttext/plain33291http://repositorio.conacyt.gov.py/bitstream/20.500.14066/4507/5/Intravenous%20sildenafil%20for%20the%20treatment%20of%20persistent%20pulmonary%20hypertension%20of%20the%20newborn%20in%20a%20resource-limited%20setting.pdf.txt5bd9a89a42f6eb6bdb76601e607e8682MD5520.500.14066/4507oai:repositorio.conacyt.gov.py:20.500.14066/45072026-02-12 19:30:39.124Repositorio Institucional CONACYTrepositorio.institucional@conacyt.gov.pyQWwgYWNlcHRhciBlc3RhIGxpY2VuY2lhLCB1c3RlZCBjb21vIGF1dG9yIHkgcHJvcGlldGFyaW8gZGUgbG9zIGRlcmVjaG9zIGRlIHByb3BpZWRhZCBpbnRlbGVjdHVhbCBkZSBzdSBvYnJhIG90b3JnYSBhbCBSZXBvc2l0b3JpbyBJbnN0aXR1Y2lvbmFsIENPTkFDWVQgZWwgZGVyZWNobyBubyBleGNsdXNpdm8gZGUgcmVwcm9kdWNjacOzbiB5IGRpc3RyaWJ1Y2nDs24gZGUgc3Ugb2JyYSBlbiBjdWFscXVpZXIgZm9ybWF0byB5IG1lZGlvLgoKQWNlcHRhIHF1ZSwgc2luIG1vZGlmaWNhciBlbCBjb250ZW5pZG8sIHNlIHB1ZWRhIGNvbnZlcnRpciBzdSBvYnJhIGEgb3RybyBmb3JtYXRvIGNvbiBmaW5lcyBkZSBwcmVzZXJ2YWNpw7NuLiBBc8OtIG1pc21vLCBhY2VwdGEgcXVlIHNlIHB1ZWRhIGNvbnNlcnZhciBtw6FzIGRlIHVuYSBjb3BpYSBwb3IgbW90aXZvcyBkZSBzZWd1cmlkYWQgeSBwcmVzZXJ2YWNpw7NuLgoKVXN0ZWQgZGVjbGFyYSBxdWUgZWwgdHJhYmFqbyBwcmVzZW50YWRvIGVzIG9yaWdpbmFsIHkgcXVlIGN1ZW50YSBjb24gbGEgcG90ZXN0YWQgcGFyYSBvdG9yZ2FyIGxvcyBkZXJlY2hvcyBkZXRhbGxhZG9zIGVuIGVzdGEgbGljZW5jaWEuIFRhbWJpw6luIGRlY2xhcmEgcXVlIHN1IG9icmEgbm8gaW5mcmluZ2UgbG8gZXN0YWJsZWNpZG8gZW4gbGEgdmlnZW50ZSBsZWdpc2xhY2nDs24gc29icmUgcHJvcGllZGFkIGludGVsZWN0dWFsLgoKU2kgbGEgb2JyYSBjb250aWVuZSBtYXRlcmlhbCBwYXJhIGVsIGN1YWwgbm8gdGllbmUgZGVyZWNob3MgZGUgYXV0b3IsIHVzdGVkIGRlY2xhcmEgcXVlIGhhIG9idGVuaWRvIGxvcyBwZXJtaXNvcyBuZWNlc2FyaW9zIGRlbCBwcm9waWV0YXJpbyBwYXJhIG90b3JnYXIgYWwgUmVwb3NpdG9yaW8gSW5zdGl0dWNpb25hbCBDT05BQ1lUIGxvcyBkZXJlY2hvcyByZXF1ZXJpZG9zIHBvciBlc3RhIGxpY2VuY2lhLCB5IHF1ZSBkaWNobyBtYXRlcmlhbCBkZSBwcm9waWVkYWQgZGUgdGVyY2Vyb3MgZXN0w6EgY2xhcmFtZW50ZSBpZGVudGlmaWNhZG8geSByZWNvbm9jaWRvIGRlbnRybyBkZWwgY29udGVuaWRvIGRlIGxhIG9icmEuCgpTaSBsYSBvYnJhIHF1ZSBkZXBvc2l0YSBoYSBzaWRvIHBhdHJvY2luYWRhIG8gZmluYW5jaWFkYSBwb3IgdW5hIG9yZ2FuaXphY2nDs24sIHVzdGVkIGRlY2xhcmEgcXVlIGhhIGN1bXBsaWRvIGNvbiBsYXMgb2JsaWdhY2lvbmVzIHJlcXVlcmlkYXMgcG9yIHRhbCBhY3VlcmRvLgoKU2kgZWwgZG9jdW1lbnRvIHNlIGJhc2EgZW4gdW5hIG9icmEgcXVlIGhhIHNpZG8gcGF0cm9jaW5hZGEgbyBhcG95YWRhIHBvciB1bmEgYWdlbmNpYSB1IG9yZ2FuaXphY2nDs24sIHNlIHByZXN1cG9uZSBxdWUgc2UgaGEgY3VtcGxpZG8gY29uIGN1YWxxdWllciBkZXJlY2hvIGRlIHJldmlzacOzbiB1IG90cmFzIG9ibGlnYWNpb25lcyByZXF1ZXJpZGFzIHBvciBlc3RlIGNvbnRyYXRvIG8gYWN1ZXJkby4KCkVsIFJlcG9zaXRvcmlvIEluc3RpdHVjaW9uYWwgQ09OQUNZVCBpZGVudGlmaWNhcsOhIGNsYXJhbWVudGUgc3UvcyBub21icmUvcyBjb21vIGVsL2xvcyBhdXRvci9lcyBvIHByb3BpZXRhcmlvL3MgZGUgbG9zIGRlcmVjaG9zIGRlbCBkb2N1bWVudG8sIHkgbm8gaGFyw6EgbmluZ3VuYSBhbHRlcmFjacOzbiBkZSBzdSBkb2N1bWVudG8gZGlmZXJlbnRlIGEgbGFzIHBlcm1pdGlkYXMgZW4gZXN0YSBsaWNlbmNpYS4K
spellingShingle Intravenous sildenafil for the treatment of persistent pulmonary hypertension of the newborn in a resource-limited setting
Mesquita Ramírez, Mirta
7. Salud
7.4. Seguimiento sanitario
Sildenafil citrate
Infant
Nitrous oxide
Newborn
Persistent fetal circulation syndrome
Vasodilator agents
Citrato de sildenafil
Lactante
Óxido nitroso
Recién nacido
Síndrome de circulación fetal persistente
Vasodilatadores
Oxygenation index
Persistent pulmonary hypertension of the newborn
Sildenafil
3. Ciencias Médicas y de la Salud
3.1. Medicina Básica (anatomía, citología, fisiología, genética, farmacia, farmacología, toxicología, inmunología e inmunohematología, química clínica, microbiología clínica, patología)
status_str publishedVersion
title Intravenous sildenafil for the treatment of persistent pulmonary hypertension of the newborn in a resource-limited setting
title_full Intravenous sildenafil for the treatment of persistent pulmonary hypertension of the newborn in a resource-limited setting
title_fullStr Intravenous sildenafil for the treatment of persistent pulmonary hypertension of the newborn in a resource-limited setting
title_full_unstemmed Intravenous sildenafil for the treatment of persistent pulmonary hypertension of the newborn in a resource-limited setting
title_short Intravenous sildenafil for the treatment of persistent pulmonary hypertension of the newborn in a resource-limited setting
title_sort Intravenous sildenafil for the treatment of persistent pulmonary hypertension of the newborn in a resource-limited setting
topic 7. Salud
7.4. Seguimiento sanitario
Sildenafil citrate
Infant
Nitrous oxide
Newborn
Persistent fetal circulation syndrome
Vasodilator agents
Citrato de sildenafil
Lactante
Óxido nitroso
Recién nacido
Síndrome de circulación fetal persistente
Vasodilatadores
Oxygenation index
Persistent pulmonary hypertension of the newborn
Sildenafil
3. Ciencias Médicas y de la Salud
3.1. Medicina Básica (anatomía, citología, fisiología, genética, farmacia, farmacología, toxicología, inmunología e inmunohematología, química clínica, microbiología clínica, patología)
url https://doi.org/10.4103/jcn.jcn_33_23
http://hdl.handle.net/20.500.14066/4507